Collaboration to strengthen PK/PD modeling approaches used in animal health
ST. LOUIS, MO – 二月 5, 2013 – Certara™, a leading provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through clinical development, announced that the Institute of Computational Comparative Medicine (ICCM) at Kansas State University has been named a Phoenix® Center of Excellence.
Certara has developed Phoenix, the leading PK/PD modeling and simulation platform, to support non-compartmental analysis, population PK/PD modeling and simulation, and IVIVC analysis. This partnership will focus on the application, validation and extension of the Phoenix platform to support studies in veterinary medicine, from toxicology to animal health. Dr. Jim Riviere recently formed the Institute of Computational Comparative Medicine (ICCM) to develop unique computational medicine capabilities that will apply to animal studies and to advance the general state of the field.
“The work we are focused on could reduce the number of animal studies required for drug approval,” said Dr. Jim Riviere, Director of the ICCM. “It could improve the determination of withdrawal times of drugs in animals with diseases; it could support the modeling of chemical risk assessment. There are many opportunities to advance veterinary medicine by using modeling and simulation methods combined with experimental data to form a quantitative framework for decision making.”
“Certara currently has six Phoenix Centers of Excellence that are focused on leveraging Phoenix to support clinical pharmacology and to train the next generation of practitioners,” said Dr. Daniel Weiner, Senior Vice President and General Manager of Certara. “We are pleased to work with Kansas State University to begin advancing the use of Phoenix to support animal health studies, aimed at both improving animal medicine as well as the reduction of animals used in clinical trials.”
Certara is dedicated to improving human health through a broad spectrum of software products and consulting services, from molecular discovery through clinical development, with special focus on supporting translational approaches to drug development. Certara was formed by uniting industry leaders Tripos®, provider of innovative scientific software solutions and services enabling life science researchers to improve the efficiency of molecular discovery; Simcyp™, a research-based company providing predictive pharmacokinetic and pharmacodynamics tools, workshops, and consultancy services; and Pharsight® Corporation, provider of software and scientific consulting services to improve productivity and decision-making in preclinical and clinical drug development. Each Certara family brand has a primary focus on a key phase within the drug discovery and development process; combined, they offer a unique set of capabilities for modeling, analysis, and simulation with scientific informatics that can enable the cross-disciplinary approaches necessary for translational science initiatives.
Diana O’Rourke, 314-951-3310
Director of Marketing